title: Vitronectin significantly influences prognosis in osteosarcoma.
abstract: Vitronectin (Vn), a multifunctional adhesive protein, is found in association with tumor progression, angiogenesis and metastasis in a variety of (human) tumors. But no studies concerning its correlation to osteosarcoma prognosis were found. Hence, we aimed to investigate the prognostic value of Vitronectin (Vn) in osteosarcoma. Here, we studied the expression of VN in the tumor tissues from 67 patients with osteosarcoma and 20 patients with osteochondroma using immunohistochemistry and estimated the effects of VN expression in osteosarcoma on progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier curve and COX proportional hazards regression model. Increased expression of VN in osteosarcoma tissue compared to no VN expression in osteochondroma tissue was shown in immunohistochemical assay. No associations were observed between VN expression and osteosarcoma patients' gender (P = 0.675), age (P = 0.813), tumor size (P = 0.436), histologic subtype (P = 0.0.543) or tumor location (P = 0.456). Univariate survival analysis demonstrated significant correlations of high VN expression with shorter PFS (P = 0.002) and OS (P = 0.001); multivariate survival analysis revealed high VN expression as a significant independent prognostic indicator for shorter PFS (HR 2.788, P = 0.003) and OS (HR2.817, P = 0.003). In conclusion, the high expression of VN in tumor cells independently indicated poor clinical prognosis in patients with osteosarcoma, other than large tumor size and non-neoadjuvant chemoradiotherapy, suggesting that VN may serve as a potential therapeutic target in osteosarcoma.
authors.affiliation: Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, P. R. China.
authors.forename: Kai
authors.initials: K
authors.lastname: Shi
authors.affiliation: Department of Central Laboratory, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, P. R. China ; Fujian Key Laboratory of Radiation Biology, Fujian Medical University Fuzhou 350005, P. R. China ; Fujian Key Laboratory of Individualized Active Immunotherapy, Fujian Medical University Fuzhou 350005, P. R. China.
authors.forename: Rui-Long
authors.initials: RL
authors.lastname: Lan
authors.affiliation: Department of Pathology, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, P. R. China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Tao
authors.affiliation: Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, P. R. China.
authors.forename: Chao-Yang
authors.initials: CY
authors.lastname: Wu
authors.affiliation: Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, P. R. China.
authors.forename: Hai-Feng
authors.initials: HF
authors.lastname: Hong
authors.affiliation: Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, P. R. China ; Department of Central Laboratory, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, P. R. China.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001859:Bone Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D059186:Chemoradiotherapy, Adjuvant; D016009:Chi-Square Distribution; D002648:Child; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy; D012516:Osteosarcoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden; D015854:Up-Regulation; D019096:Vitronectin / Q000032:analysis*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D019096:Vitronectin
keywords: Vitronectin; immunohistochemistry; osteosarcoma; prognosis